Evidence map›Paper›PMID 41446307›Full record

ArticleFrontiers in psychiatry2025

How do psychedelics impact people with a history of non-affective psychosis? A qualitative study.

Haley Maria Dourron, Heith Copes, Daniel H Grossman, Melissa Bradley, Christopher R Nicholas, Jessica A Turner, Gaige Allen-Clark, Maggie Gossage, Peter S Hendricks

Abstract read
In one paragraph

Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haley Maria DourronCenter for Social and Affective Neuroscience, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Heith CopesDepartment of Criminal Justice, University of Alabama at Birmingham, Birmingham, AL, United States.
Daniel H GrossmanDepartment of Psychology, University of Alabama at Birmingham, Birmingham, AL, United States.
Melissa BradleyDepartment of Psychiatry and Behavioral Neurobiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Christopher R NicholasDepartment of Family Medicine and Community Health, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, United States.
Jessica A TurnerDepartment of Psychiatry and Behavioral Health, The Ohio State University, Columbus, OH, United States.
Gaige Allen-ClarkIndependent Researcher, Los Angeles, CA, United States.
Maggie GossageDepartment of Psychiatry and Behavioral Neurobiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Peter S HendricksDepartment of Psychiatry and Behavioral Neurobiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: People with a history of psychotic disorders are excluded from contemporary trials of psychedelic-assisted therapy. Although survey studies have explored the impact of naturalistic psychedelic use on people with a history of psychotic disorders, a qualitative study has yet to examine the subjective effects of psychedelic use in this population during both the acute effects and perceived long-term impacts. Method: Two semi-structured in-depth interviews were conducted with participants (n = 19) who had used psychedelics after the diagnosis of non-affective psychotic disorders (NAPD). Interviews probed the perceived positive and negative effects of psychedelic use. Data were analyzed using reflexive thematic analysis. Results: We constructed three major themes: 1) common challenges during the acute effects of psychedelics; 2) psychosis-specific psychedelic experiences; and 3) post-acute and long-term effects. In the common challenges of psychedelic use theme, participants often described experiences with transient anxiety, which sometimes resulted in brief self-reported hospitalizations. In the psychosis-specific psychedelic experiences theme, the subthemes consisted of psychedelics during and after psychosis, self-compassion and reduced self-stigma, and insight into hallucinations and delusions. The post-acute and long-term effects theme included subthemes of positive effects, negative effects, and a lack of long-term effects. Overall, most participants described some benefits of psychedelics, but the durability of perceived benefits varied widely. Conclusion: Psychedelics might have heterogeneous impacts on people with NAPD, including both risks for harm and potential benefits. Our findings may assist in the development of safety and tolerability trials, highlighting the need for more nuanced work that examines how psychedelics impact people with NAPD.

Indexed as

harm reductionpsychedelicspsychosisqualitative researchschizophrenia

Identifiers

PMID41446307
PMCPMC12722819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.